BridgeMD
New treatment option for Brain Metastases
Official title The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
ClinicalTrials.gov ID: NCT05378633
What this study is testing
- What it's testing
- Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life. Therapy options for multiple brain metastases may vary and range from stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), chemotherapy, immunotherapy to palliative best supportive care.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- histologically confirmed malignant illness
- 4-15 suspect intracranial lesions, taking into consideration all available MRI series
- age ≥ 18 years of age
- For women with childbearing potential, (and men) adequate contraception.
- Ability of subject to understand character and individual consequences of the clinical trial
You likely can't join if
- Refusal of the patients to take part in the study
- Inability to tolerate irradiation consistent with the protocol
- Small-cell lung cancer (SCLC) or lymphoma as primary malignant illness
- \>15 suspect intracranial lesions, taking into consideration all available MRI series
- leptomeningeal disease
- Previous radiotherapy of the brain
See the full eligibility criteria
- histologically confirmed malignant illness
- 4-15 suspect intracranial lesions, taking into consideration all available MRI series
- age ≥ 18 years of age
- For women with childbearing potential, (and men) adequate contraception.
- Ability of subject to understand character and individual consequences of the clinical trial
- Written informed consent (must be available before enrolment in the trial)
- Refusal of the patients to take part in the study
- Inability to tolerate irradiation consistent with the protocol
- Small-cell lung cancer (SCLC) or lymphoma as primary malignant illness
- \>15 suspect intracranial lesions, taking into consideration all available MRI series
- leptomeningeal disease
- Previous radiotherapy of the brain
- Patients who have not yet recovered from acute high-grade toxicities of prior therapies
- Pregnant or lactating women
- Participation in another competing clinical study or observation period of competing trials, respectively
- MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants)
The study team makes the final eligibility decision.
Where it's taking place
- Heidelberg, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Heidelberg, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.